Programs

Presentations and Publications

Recent Medical Meeting Presentations | Voxelotor Data Publications | Voxelotor Mechanism of Action Publications | Selected Key Sickle Cell Disease ResearchSelected Key Transcranial Doppler Research

At GBT, we collaborate with academic centers to present and publish key results at medical conferences and in peer-reviewed publications. For additional information related to our data presentations and publications, please contact 1-833-GBT-4YOU (1-833-428-4968).



Recent Medical Meeting Presentations

61st American Society of Hematology Annual Meeting & Exposition (2019)

Poster Presentation
Abstract #130767
Concomitant Hydroxyurea and Voxelotor: Results from the HOPE Study

Poster Presentation
Abstract #130802
Correlation of Voxelotor Exposure with Hemoglobin Response and Measures of Hemolysis in Patients from the HOPE Study

Poster Presentation
Abstract #131177
Transcranial Doppler Velocities Conversion Rate Based on Increasing Hemoglobin Concentration: Analysis from the SCCRIP Cohort Study

Poster Presentation
Abstract #124933
Chronic Kidney Disease is Under-Screened in SCD and Mild Albuminuria is Associated with a Drop in Hemoglobin: A Report from the GRNDaD Sickle Cell Registry

Poster Presentation
Abstract #129026
Incidence of Vaso-occlusive Crisis Does Not Increase with Achieving Higher Hemoglobin Levels on Voxelotor Treatment or After Discontinuation: Analyses of the HOPE Study

Poster Presentation
Abstract #129351
Improvement in Red Blood Cell Physiology in Children with Sickle Cell Anemia Receiving Voxelotor

Poster Presentation
Abstract #127173
Economic Burden of End Organ Damage Among Patients with Sickle Cell Disease in the US

Poster Presentation
Abstract #129282
Pharmacological Increase of Hb-O2 Affinity with a Voxelotor Analog Does Not Decrease Brain Tissue pO2 or Limit O2 Extraction in Brain Tissues of Sickle Cell Mice



24th European Hematology Association (EHA) Congress (2019)

Presidential Symposium / Oral Presentation
Results From the Randomized, Placebo-Controlled, Phase 3 Hemoglobin Oxygen Affinity Modulation to Inhibit HbS Polymerization (HOPE) Trial of Voxelotor in Adults and Adolescents With Sickle Cell Disease

Poster Presentation
Cerebral Blood Flow in Adolescents with Sickle Cell Anemia Receiving Voxelotor

Poster Presentation
Central Physiologic Mechanisms Which Augment O2 Release (Bohr Effect and 2,3-DPG Binding) Are Preserved in the Presence of Voxelotor at the Therapeutic Target of 30% Hb Modification



60th American Society of Hematology Annual Meeting & Exposition (2018)

Oral Presentation
Low Hemoglobin Increases Risk for Stroke, Kidney Disease, Elevated Pulmonary Artery Systolic Pressure, and Premature Death in Sickle Cell Disease: A Systematic Literature Review and Meta-Analysis

Oral Presentation
Results from Part A of the Hemoglobin Oxygen Affinity Modulation to Inhibit HbS Polymerization (HOPE) Trial (GBT440-031), a Placebo-Controlled Randomized Study Evaluating Voxelotor (GBT440) in Adults and Adolescents with Sickle Cell Disease

Oral Presentation
Interim Results From a Phase 2a Study (GBT440-007) Evaluating Adolescents With Sickle Cell Disease Treated with Multiple Doses of Voxelotor (GBT440)

Poster Presentation
Societal Costs of Sickle Cell Disease in the United States